Pharmacological interventions to improve sleep in people with Alzheimer’s disease: a meta-analysis of randomized controlled trials

References

• Zhang Y, Ren R, Yang L, et al. Sleep in Alzheimer’s disease: a systematic review and meta-analysis of polysomnographic findings. Transl Psychiatry. 2022;12(1):136. doi: 10.1038/s41398-022-01897-y
   PubMed Web of Science ®Google Scholar
• Caglayan C, Demir Y, Kucukler S, et al. The effects of hesperidin on sodium arsenite-induced different organ toxicity in rats on metabolic enzymes as antidiabetic and anticholinergics potentials: a biochemical approach. J Food Biochem. 2019;43(2):e12720. doi: 10.1111/jfbc.12720
   PubMed Web of Science ®Google Scholar
• Özbey F, Taslimi P, Gülçin I, et al. Synthesis of diaryl ethers with acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase inhibitory actions. J Enzyme Inhib Med Chem. 2016;31(sup 2):79–85. doi: 10.1080/14756366.2016.1189422
   PubMedGoogle Scholar
• Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ (Online). 2019;367:l6217–l6217. doi: 10.1136/bmj.l6217
   PubMed Web of Science ®Google Scholar
• Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer’s Disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):yv055–pyv055. doi: 10.1093/ijnp/pyv055
   Web of Science ®Google Scholar
• Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481–5503. doi: 10.1038/s41380-021-01249-0
   PubMed Web of Science ®Google Scholar
• Mielke MM, Aggarwal NT, Vila‐Castelar C, et al. Consideration of sex and gender in Alzheimer’s disease and related disorders from a global perspective. Alzheimer’s Dementia. 2022;18(12):2707–2724.
   PubMed Web of Science ®Google Scholar
• Zhou G, Liu S, Yu X, et al. High prevalence of sleep disorders and behavioral and psychological symptoms of dementia in late-onset Alzheimer disease. Medicine. 2019;98(50):e18405. doi: 10.1097/md.0000000000018405
   PubMed Web of Science ®Google Scholar
• Lim MM, Gerstner JR, Holtzman DM. The sleep–wake cycle and Alzheimer’s disease: what do we know? Neurodegener Dis Manag. 2014;4(5):351–362.
   PubMedGoogle Scholar
• Suni E, Singh A. Circadian rhythm, what it is, what shapes it and why its fundamental to getting quality sleep. Sleep Foundation 2023 [cited Feb 16]. Available from: www.sleepfoundation.org/circadian-rhythm.
   Google Scholar
• Vitiello MV, Borson S. Sleep disturbances in patients with Alzheimer’s Disease. CNS Drugs. 2001;15(10):777–796. doi: 10.2165/00023210-200115100-00004
   PubMed Web of Science ®Google Scholar
• Vanderheyden WM, Lim MM, Musiek ES, et al. Alzheimer’s disease and sleep–wake disturbances: amyloid, astrocytes, and animal models. J Neurosci. 2018;38(12):2901–2910. doi: 10.1523/JNEUROSCI.1135-17.2017
   PubMed Web of Science ®Google Scholar
• Gao F, Liu T, Tuo M, et al. The role of orexin in Alzheimer disease: from sleep-wake disturbance to therapeutic target. Neurosci Lett. 2021;765:136247–136247. doi: 10.1016/j.neulet.2021.136247
   PubMed Web of Science ®Google Scholar
• Carvalho DZ, St Louis EK, Knopman DS, et al. Association of excessive daytime sleepiness with longitudinal β-amyloid accumulation in elderly persons without dementia. JAMA Neurol. 2018;75(6):672–680. doi: 10.1001/jamaneurol.2018.0049
   PubMed Web of Science ®Google Scholar
• Brzecka A, Leszek J, Ashraf GM, et al. Sleep disorders associated with Alzheimer’s disease: a perspective. Front Neurosci. 2018;12:330–330. doi: 10.3389/fnins.2018.00330
   PubMed Web of Science ®Google Scholar
• Ooms S, Overeem S, Besse K, et al. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71(8):971–977. doi: 10.1001/jamaneurol.2014.1173
   PubMed Web of Science ®Google Scholar
• Troussière AC, Charley CM, Salleron J, et al. Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2014;85(12):1405–1408.
   PubMed Web of Science ®Google Scholar
• McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014;21(3):CD009178. doi: 10.1002/14651858.CD009178.pub2
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• MetaXL Version 5.3. 2019. https://www.epigear.com/index_files/metaxl.html
   Google Scholar
• Serfaty M, Kennell-Webb S, Warner J, et al. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry. 2002;17(12):1120–1127. doi: 10.1002/gps.760
   PubMed Web of Science ®Google Scholar
• Asayama K, Yamadera H, Ito T, et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334–341. doi: 10.1272/jnms.70.334
   PubMedGoogle Scholar
• Markowitz JS, Gutterman EM, Lilienfeld S, et al. Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep. 2003;26(5):602–606. doi: 10.1093/sleep/26.5.602
   PubMed Web of Science ®Google Scholar
• Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s Disease. Sleep. 2003;26(7):893–901. doi: 10.1093/sleep/26.7.893
   PubMed Web of Science ®Google Scholar
• Dowling GA, Burr RL, Van Someren EJW, et al. Melatonin and bright-light treatment for rest–activity disruption in institutionalized patients with Alzheimer’s Disease. J Am Geriatr Soc. 2008;56(2):239–246.
   PubMed Web of Science ®Google Scholar
• Moraes W, Poyares D, Sukys-Claudino L, et al. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study. Chest. 2008;133(3):677–683. doi: 10.1378/chest.07-1446
   PubMed Web of Science ®Google Scholar
• Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Ame J Geriatr Psychiatry. 2009;17(2):166–169. doi: 10.1097/JGP.0b013e318187de18
   PubMed Web of Science ®Google Scholar
• Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–1574. doi: 10.1016/j.jagp.2013.12.174
   PubMed Web of Science ®Google Scholar
• Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–961. doi: 10.2147/CIA.S65625
   PubMed Web of Science ®Google Scholar
• Grippe TC, Goncalves BS, Louzada LL, et al. Circadian rhythm in Alzheimer disease after trazodone use. Chronobiol Int. 2015;32(9):1311–1314.
   PubMed Web of Science ®Google Scholar
• Herring WJ, Ceesay P, Snyder E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial. Alzheimer’s Dementia. 2020;16(3):541–551.
   PubMed Web of Science ®Google Scholar
• Moline M, Thein S, Bsharat M, et al. Safety and efficacy of lemborexant in patients with irregular sleep-wake rhythm disorder and Alzheimer’s Disease dementia: results from a phase 2 randomized clinical trial. J Prev Alzheimers Dis. 2021;8(1):1–12.
   Web of Science ®Google Scholar
• Huo S, Cheng L, Li S, et al. Effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer’s disease and sleep disorder: a randomized controlled trial. Brain Behav. 2022;12(2):e2488. doi: 10.1002/brb3.2488
   PubMed Web of Science ®Google Scholar
• Louzada LL, Machado FV, Quintas JL, et al. The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial. Neuropsychopharmacology. 2022;47(2):570–579.
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol. 2010;8(3):218–227. doi: 10.2174/157015910792246209
   PubMed Web of Science ®Google Scholar
• Hamuro A, Honda M, Wakaura Y. Suvorexant for the treatment of insomnia in patients with Alzheimer’s disease. Aust NZJ Psychiatry. 2018;52(2):207–208. doi: 10.1177/0004867417747402
   PubMed Web of Science ®Google Scholar
• Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259–267.
   PubMed Web of Science ®Google Scholar
• Banerjee I. Orexin receptor competitive antagonists: a novel target of the sedative and hypnotics drugs for the pharmacotherapy of Insomnia. Nepal J Epidemiol. 2018;8(1):713–715. doi: 10.3126/nje.v8i1.21139
   PubMedGoogle Scholar
• Lader M. Zopiclone: Is there any dependence and abuse potential? J Neurol. 1997;244(S1):S18–S22. doi: 10.1007/BF03160567
   PubMedGoogle Scholar
• Gonçalo AMG, Vieira-Coelho MA. The effects of trazodone on human cognition: a systematic review. Eur J Clin Pharmacol. 2021;77(11):1623–1637. doi: 10.1007/s00228-021-03161-6
   PubMed Web of Science ®Google Scholar
• Karageorgiou E, La A, Krystal A, et al. F2‐05‐04: slow wave sleep enhancers as a potential therapeutic approach in delaying cognitive decline in Alzheimer’s disease: the trazodone paradigm. Alzheimers Dement. 2019;15(7S_Part_10):524–P524.
   Google Scholar
• Javed B, Javed A, Kow CS, et al. Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer’s disease. Expert Rev Neurother. 2023;23(6):501–514. doi: 10.1080/14737175.2023.2214316
   PubMedGoogle Scholar